Actively Recruiting
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Led by Mayo Clinic · Updated on 2026-03-05
50
Participants Needed
1
Research Sites
1061 weeks
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
CONDITIONS
Official Title
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of postural tachycardia syndrome (POTS) with heart rate increase of 30 beats per minute or more within 5 minutes of head-up tilt
- Symptoms of orthostatic intolerance including weakness, lightheadedness, blurred vision, nausea, palpitations, or difficulty concentrating
- Age between 15 and 55 years
You will not qualify if you...
- Pregnant or breastfeeding women
- Other organ system failure or systemic illness affecting autonomic function or study cooperation
- Hypothyroidism or hyperthyroidism
- Clinically significant coronary artery disease
- Medications that interfere with autonomic testing
- Previous treatment with pyridostigmine for POTS within the past month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here